Type 1 diabetes is a chronic disease in which the immune system attacks and destroys insulin-producing beta cells in the pancreas, resulting in high blood levels of glucose. A study published January 4th in Cell Stem Cell demonstrates that a gene therapy approach can lead to the long-term survival of functional beta cells as well as normal blood glucose levels for an extended period of time in mice with diabetes. The researchers used an adeno-associated viral (AAV) vector to deliver to the mouse pancreas two proteins, Pdx1 and MafA, which reprogrammed plentiful alpha cells into functional, insulin-producing beta cells.
“This study is essentially the first description of a clinically translatable, simple single intervention in autoimmune diabetes that leads to normal blood sugars, and importantly with no immunosuppression,” says senior study author George Gittes of the University of Pittsburgh School of Medicine. “A clinical trial in both type 1 and type 2 diabetics in the immediate foreseeable future is quite realistic, given the impressive nature of the reversal of the diabetes, along with the feasibility in patients to do AAV gene therapy.”
Approximately 9% of the world’s adult population has diabetes, which can cause serious health problems such as heart disease, nerve damage, eye problems, and kidney disease. One fundamental goal of diabetes treatment is to preserve and restore functional beta cells, thereby replenishing levels of a hormone called insulin, which moves blood glucose into cells to fuel their energy needs. But in patients with type 1 diabetes, beta-cell replacement therapy is likely doomed to failure because the new cells might fall victim to the same autoimmunity that destroyed the original cells.
A potential solution to this problem is to reprogram other cell types into functional beta-like cells, which can produce insulin but are distinct from beta cells and therefore are not recognized or attacked by the immune system. To explore the feasibility of this approach, Gittes and first author Xiangwei Xiao of the University of Pittsburgh School of Medicine engineered an AAV vector to deliver to the mouse pancreas proteins called Pdx1 and MafA, which support beta cell maturation, proliferation, and function. The goal was to generate functional beta-like cells from pancreatic alpha cells, which may be the ideal source for beta cell replacement. For example, alpha cells are plentiful, resemble beta cells, and are in the correct location, all of which could facilitate reprogramming.
By comparing the gene expression patterns of normal beta cells and insulin-producing cells derived from alpha cells, the researchers confirmed nearly complete cellular reprogramming. This gene therapy approach restored normal blood glucose levels in diabetic mice for an extended period of time, typically around four months, and the new insulin-producing cells derived almost exclusively from alpha cells. Moreover, the strategy successfully generated functional insulin-producing cells from human alpha cells.
“The viral gene therapy appears to create these new insulin-producing cells that are relatively resistant to an autoimmune attack,” Gittes says. “This resistance appears to be due to the fact that these new cells are slightly different from normal insulin cells, but not so different that they do not function well.”
Several features of this approach could facilitate translation to humans. For one, AAV vectors like those used in this study are currently undergoing various gene therapy trials in humans. Moreover, the viral vectors can be delivered directly to the human pancreas through a routinely performed non-surgical endoscopic procedure; however, this procedure can elicit pancreatic inflammation. In addition, no immunosuppression is required, so patients would avoid related side effects such as an increased risk of infection.
However, one major concern was that the mice did eventually return to the diabetic state, suggesting that this treatment would not represent a definitive cure for the disease. “The protection from recurrent diabetes in the mice was not permanent, although some studies would suggest that processes in mice are highly accelerated, so four months in mice might translate to several years in humans,” Gittes says.
Currently, the researchers are testing their approach in primates. “If we are able to show efficacy in non-human primates, we will begin work with the FDA to get approval for the use of this viral gene therapy in diabetic patients, both type 1 and type 2,” Gittes says.
The Latest on: Type 1 diabetes
via Google News
The Latest on: Type 1 diabetes
- Engineered T cells for type 1 diabetes move closer to clinicon June 3, 2020 at 11:02 am
For much of the last decade, Dr. David Rawlings, director of Seattle Children's Research Institute's Center for Immunity and Immunotherapies, has dreamed of developing a therapy for children with type ...
- Fighting Off Job Discrimination with Type 1 Diabetes During COVID-19on June 3, 2020 at 3:18 am
Have type 1 diabetes and being forced to work during the pandemic? Here are the legal resources you need to know.
- Type 1 diabetes costs $2,500 a year with insuranceon June 2, 2020 at 2:13 pm
Out-of-pocket costs for Americans with Type 1 diabetes average $2,500 a year, a new study says. But 8 percent of patients have more than $5,000 in out-of-pocket costs, possibly due to having ...
- Cost of Type 1 Diabetes: $2,500 a Year With Insuranceon June 2, 2020 at 9:49 am
TUESDAY, June 2, 2020 (HealthDay News) -- Out-of-pocket costs for Americans with type 1 diabetes average $2,500 a year, a new study says. But 8% of patients have more than $5,000 in out-of-pocket ...
- Out-of-pocket health care costs for patients with type 1 diabetes is $2,500 a year, study revealson June 1, 2020 at 10:29 am
Adults and children with type 1 diabetes will spend an average of $2,500 a year out-of-pocket for health care - but insulin isn't always the biggest expense - new research suggests.
- People with type 1 diabetes spend $2,500 a year in health care costson June 1, 2020 at 8:01 am
Adults and children with type 1 diabetes will spend an average of $2,500 a year out-of-pocket for health care—but insulin isn't always the biggest expense—new research suggests.
- Coronavirus and diabetes: the different risks for people with type 1 and type 2on June 1, 2020 at 3:09 am
New data shows the threat posed by COVID-19 differs significantly between people with type 1 and type 2 diabetes.
- Role of DNA-LL37 complexes in the activation of plasmacytoid dendritic cells and monocytes in subjects with type 1 diabeteson June 1, 2020 at 2:26 am
Initiation of type 1 diabetes (T1D) is marked by the infiltration of plasmacytoid dendritic cells (pDCs) and monocytes in pancreatic islets. Dying beta cells release self-DNA, which forms complexes ...
- Navigating the COVID-19 Pandemic as a Parent With Type 1 Diabeteson June 1, 2020 at 12:17 am
Allison C. discusses her experiences as a parent with type 1 diabetes with kids at home during the COVID-19 lockdown.
- Lockdown Bonus: Tighter Glucose Control in Type 1 Diabeteson May 29, 2020 at 8:51 am
In two European studies, time-in-range measured using continuous glucose monitoring improved among adults with type 1 diabetes confined at home during COVID-19 quarantine.
via Bing News